{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:16:36Z","timestamp":1762866996808},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.leukres.2016.12.002","type":"journal-article","created":{"date-parts":[[2016,12,12]],"date-time":"2016-12-12T02:15:56Z","timestamp":1481508956000},"page":"39-49","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation"],"prefix":"10.1016","volume":"53","author":[{"given":"Max J.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Tardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc M.","family":"Loriaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen E.","family":"Spurgeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elie","family":"Traer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor","family":"Kovacsovics","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence D.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.leukres.2016.12.002_bib0005","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-06-0118","article-title":"Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice","volume":"5","author":"Mayer","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.leukres.2016.12.002_bib0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","article-title":"In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy","volume":"33","author":"Tardi","year":"2009","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.leukres.2016.12.002_bib0015","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","article-title":"Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts","volume":"34","author":"Lim","year":"2010","journal-title":"Leuk. Res."},{"issue":"8","key":"10.1016\/j.leukres.2016.12.002_bib0020","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3109\/10428194.2010.490312","article-title":"Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts","volume":"51","author":"Lim","year":"2010","journal-title":"Leuk. Lymphoma"},{"issue":"21","key":"10.1016\/j.leukres.2016.12.002_bib0025","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2016.12.002_bib0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cncr.28974","article-title":"Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML","volume":"121","author":"Cortes","year":"2015","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.leukres.2016.12.002_bib0035","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","article-title":"First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia","volume":"29","author":"Feldman","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2016.12.002_bib0040","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.leukres.2012.07.006","article-title":"Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia","volume":"36","author":"Feldman","year":"2012","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.leukres.2016.12.002_bib0045","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.exphem.2011.04.001","article-title":"Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells","volume":"39","author":"Kim","year":"2011","journal-title":"Exp. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2016.12.002_bib0050","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.bbmt.2013.04.013","article-title":"A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia","volume":"19","author":"Gergis","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"12","key":"10.1016\/j.leukres.2016.12.002_bib0055","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nrc4015","article-title":"Precision medicine for cancer with next-generation functional diagnostics","volume":"15","author":"Friedman","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"21","key":"10.1016\/j.leukres.2016.12.002_bib0060","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1073\/pnas.0903233106","article-title":"RNAi screen for rapid therapeutic target identification in leukemia patients","volume":"106","author":"Tyner","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.leukres.2016.12.002_bib0065","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/0008-5472.CAN-12-1906","article-title":"Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening","volume":"73","author":"Tyner","year":"2013","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.leukres.2016.12.002_bib0070","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1535-7163.MCT-10-1044","article-title":"Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies","volume":"10","author":"Gozgit","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.leukres.2016.12.002_bib0075","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2016.12.002_bib0080","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ccr.2012.08.027","article-title":"Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia","volume":"22","author":"Bicocca","year":"2012","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.leukres.2016.12.002_bib0085","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/pbc.23383","article-title":"In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia","volume":"59","author":"Glover","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"issue":"19","key":"10.1016\/j.leukres.2016.12.002_bib0090","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.leukres.2016.12.002_bib0095","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2013.228","article-title":"CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway","volume":"27","author":"Prins","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2016.12.002_bib0100","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/2159-8290.CD-12-0504","article-title":"TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia","volume":"3","author":"Sanda","year":"2013","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.leukres.2016.12.002_bib0105","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1124\/jpet.112.200832","article-title":"The selective SYK inhibitor P 505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia","volume":"344","author":"Spurgeon","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.leukres.2016.12.002_bib0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1158\/0008-5472.CAN-15-0817","article-title":"Identification and characterization of tyrosine kinase nonreceptor 2 mutations in leukemia through integration of kinase inhibitor screening and genomic analysis","volume":"76","author":"Maxson","year":"2016","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.leukres.2016.12.002_bib0115","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1158\/0008-5472.CAN-14-1576","article-title":"Therapeutically targetable ALK mutations in leukemia","volume":"75","author":"Maxson","year":"2015","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.leukres.2016.12.002_bib0120","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0005-2736(92)90084-Y","article-title":"In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release","volume":"1109","author":"Horowitz","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"issue":"23","key":"10.1016\/j.leukres.2016.12.002_bib0125","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1182\/blood.V126.23.2510.2510","article-title":"CPX-351 ((cytarabine:daunorubicin) liposome injection, (vyxeos)) does not prolong QTcF intervals, requires no dose adjustment for impaired renal function and induces high rates of complete remission in acute myeloid leukemia","volume":"126","author":"Lin","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2016.12.002_bib0130","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.leukres.2016.12.002_bib0135","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/sj.leu.2400770","article-title":"Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia","volume":"11","author":"Horiike","year":"1997","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2016.12.002_bib0140","first-page":"1911","article-title":"Internal tandem duplication of the flt3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2016.12.002_bib0145","unstructured":"Celator Pharmaceuticals. Celator Announces Phase 3 Trial for VYXEOS\u2122 (CPX-351) in Patients with High-Risk AML Demonstrates Statistically Significant Improvement in Overall Survival (2016) Available from: http:\/\/ir.celatorpharma.com\/releasedetail.cfm?releaseid=946014."},{"key":"10.1016\/j.leukres.2016.12.002_bib0150","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/blood.V116.21.2886.2886","article-title":"Evaluation of CPX-351 (cytarabine:daunorubicin) liposome injection anti-Leukemic activity against primary patient leukemia cells","volume":"116","author":"Tyner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.12.002_bib0155","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.7100","article-title":"Multivariate analysis of factors affecting overall survival, event free survival, and 60-day mortality among AML patients treated with CPX-351 or intensive therapy","volume":"31","author":"Feldman","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2016.12.002_bib0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/pbc.25133","article-title":"Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program","volume":"62","author":"Carol","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"6","key":"10.1016\/j.leukres.2016.12.002_bib0165","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.12.002_bib0170","first-page":"135258","article-title":"CPX-351 treatment of previously untreated older aml patients with high risk aml markedly increases the response rate over 7+3 in patients with FLT3 mutations","author":"Lancet","year":"2016","journal-title":"EHA Learn. Center"},{"key":"10.1016\/j.leukres.2016.12.002_bib0175","first-page":"102s","article-title":"Scavenger receptor class B type I (SR-B1) expression levels modulate CPX-351 uptake within cancer cells","author":"Kim","year":"2014","journal-title":"Proc. Can. Soc. Pharm. Sci."},{"key":"10.1016\/j.leukres.2016.12.002_bib0180","article-title":"Selective tumor localization of CRLX101, an investigational novel nanoparticle-drug conjugate","author":"Peters","year":"2015","journal-title":"AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"},{"issue":"4768","key":"10.1016\/j.leukres.2016.12.002_bib0185","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1126\/science.3090687","article-title":"Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins","volume":"233","author":"Bar-Sagi","year":"1986","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.leukres.2016.12.002_bib0190","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1158\/0008-5472.CAN-14-2211","article-title":"Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein","volume":"75","author":"Kamphorst","year":"2015","journal-title":"Cancer Res."},{"issue":"7451","key":"10.1016\/j.leukres.2016.12.002_bib0195","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nature12138","article-title":"Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells","volume":"497","author":"Commisso","year":"2013","journal-title":"Nature"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616302648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616302648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T18:26:38Z","timestamp":1657995998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616302648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":39,"alternative-id":["S0145212616302648"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.12.002","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}